US Patent Issued to CYTOMX THERAPEUTICS on Feb. 10 for "Single-and multi-chain polypeptides that bind specifically to CD3 epsilon" (California Inventors)

ALEXANDRIA, Va., Feb. 11 -- United States Patent no. 12,545,731, issued on Feb. 10, was assigned to CYTOMX THERAPEUTICS INC. (South San Francisco, Calif.).

"Single-and multi-chain polypeptides that bind specifically to CD3 epsilon" was invented by Christopher Kemball (South San Francisco, Calif.), Pia Challita-Eid (South San Francisco, Calif.) and Rene Hubert (South San Francisco, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are single-chain polypeptides and multi-chain polypeptides that bind specifically to CD3 epsilon (CD3Epsilon). Also provided herein are anti-idiotypic antibodies that bind specifically to any of the antigen-binding domains described herein."

The patent was filed...